BP 110
Alternative Names: BP-110Latest Information Update: 27 Apr 2023
At a glance
- Originator Brillian Pharma
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder
Most Recent Events
- 18 Apr 2023 Preclinical trials in Attention-deficit hyperactivity disorder (Adjunctive treatment) in USA (PO) (Brillian Pharma pipeline, April 2023)
- 18 Apr 2023 Preclinical trials in Attention-deficit hyperactivity disorder (Monotherapy) in USA (PO) (Brillian Pharma pipeline, April 2023)
- 18 Aug 2022 Brillian Pharma has a patent pending for pharmaceutical unit dose systems for oral dry solution and suspension in USA